RecruitingNCT05672043

Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China

Perspective Study on Genetic Predispositions and Clinical Prognosis of Children and Adolescents With Malignant Brain Neoplasms in China

Sponsor

Beijing Tiantan Hospital

Enrollment

400 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Germ Cell Tumor Glioma Brain Tumor, Pediatric Medulloblastoma Ependymoma Central Nervous System Tumor, Pediatric

Summary

Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.

Eligibility

Min Age: 0 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects genetic and molecular data from children and teenagers in China who have been diagnosed with malignant brain tumors, such as medulloblastoma, glioma, or other CNS cancers. The goal is to build a better understanding of the biology of these tumors to improve future treatment strategies. **You may be eligible if...** - You are between 0 and 18 years old - You have been diagnosed with a malignant brain or central nervous system tumor - You are scheduled for and eligible to receive surgical tumor removal - The diagnosis has been confirmed by a specialist neuropathologist - You and/or your parents/guardians consent to participation **You may NOT be eligible if...** - You are not eligible for surgery - Your tumor has not been confirmed as malignant by a neuropathologist - You or your guardians do not consent to joining the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Beijing Tiantan Hosiptal

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05672043

Related Trials

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT073265664 locations

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT074649253 locations

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

NCT055555501 location

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

NCT0469602924 locations

Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

NCT040657762 locations